Origin

A standardized complex of neuropeptides and free amino acids derived from porcine brain tissue, developed in Austria and used clinically in Europe and Asia since the 1970s-80s for stroke, dementia, and Alzheimer's disease.

Mechanism

Modulates inflammatory cytokines, reducing IL-1β and IL-6 while boosting IL-10, enhances neurotrophic signaling, promotes neuroplasticity (dendritic spine density in hippocampus and cortex), and stabilizes the blood-brain barrier.

Research summary

Evidence

Neuroprotective effects are documented in in-vitro stroke and TBI models, with improved memory and increased hippocampal spine density in animal models. Clinical trials in dementia and vascular cognitive impairment show modest cognitive benefits, particularly post-stroke, mostly from European and Eastern European institutions. No large US FDA-track trials have been completed.

Evidence tier: Approved in 40+ countries; not FDA-approved in US — see the methodology note for how this is assessed.

Citations

Cerebrolysin treatment improved short-term memory deficits while simultaneously increasing hippocampal spine density in hypertensive female rats — Espinoza et al. 2025

Reported benefits

cognitive support in dementia
stroke recovery
post-TBI neuroprotection
neuroinflammation reduction

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
Route	Reported protocol
Intravenous or intramuscular injection	Typically 30 mL (1000-1500 mg) daily for 10-20 days in clinical trials; varies by indication.

Side effects

generally well tolerated
rare local injection-site reactions
rare mild allergic responses

Safety notes

Community & reddit notes (anecdotal — not clinical evidence)

Nootropic users report modest subjective cognitive benefit. Legal and available by prescription or import in many non-US jurisdictions.